A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

AVI Biopharma

About Avi Biopharma:

AVI is a biopharmaceutical company developing drugs to treat life-threatening diseases using third-generation antisense technology. They have completed eleven clinical trials with their NeuGene® antisense drugs in more than 300 subjects addressing cardiovascular restenosis, cancer, polycystic kidney disease and drug metabolism.

Their most advanced clinical program is in cardiovascular restenosis. They have completed Phase II trials evaluating their antisense drug, Resten-NG

Their NeuGene drug candidates have shown antiviral activity in preclinical and field trials against a broad group of RNA viruses, including hepatitis C virus, West Nile virus, SARS coronavirus, Dengue fever virus and Ebola virus.

AVI has evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer.

Pipeline Chart for Avi Biopharma

NeuGene Clinical Development Chart --NeuGene antisense compounds include use in drug metabolism and in treating cardiovascular disease, cancer, polycystic kidney disease, and viral diseases


More on Avi Biopharma

Home Page

Key Statistics fo Avi Biopharma

Basic Chart for Avi Biopharma

Analyst Opinion

Analysts Estimates

Headline News

Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.